$ENS

EnerSys to acquire Ultralife for $320 million

EnerSys (ENS) to acquire Ultralife (ULBI) for $320M, or $16 per share. The deal, expected to close in Q1 2027, aims to expand EnerSys's defense power platform. Ultralife generated $191M revenue in fiscal 2025. EnerSys expects $15-20M in annual cost synergies within 18 months.

Original reporting
Published Oct 29, 2026, 11:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
EnerSys to acquire Ultralife for $320 million — source image
Decision brief

The 30-second read

$ENSBullishMed
01

Why it matters

The acquisition creates a larger, diversified defense battery platform, potentially improving market share and pricing power in a growing defense sector.

02

Market read

The $320 million deal is material for both companies and introduces a clear price catalyst for Ultralife shares while adding strategic depth to EnerSys.

03

What to watch

Regulatory approval risk and potential antitrust scrutiny in defense contracts could delay or alter the transaction.

Relevance 8/10Novelty 8/10Timing: immediate reaction to announcement; tender offer to commence shortly after filing

Background

EnerSys (NYSE: ENS) is a global leader in stored energy solutions for industrial, infrastructure, and defense applications. Ultralife (NASDAQ: UL) supplies specialized batteries for military communications and other niche markets.

Company-level read

Ticker impact

$ENSBullishHigh confidence
Context

EnerSys announced a definitive agreement to acquire Ultralife for $320 million at $16 per share in cash.

Expected impact

likely modest pressure as investors price in the cash outlay and integration risk, but long‑term upside from defense exposure.

Evidence & confidence

The deal size is material for a mid‑cap (ENS) and the terms are disclosed for the first time, creating a clear near‑term valuation impact.

Market effects

Consolidation in the defense battery market may pressure peers such as Exide (XIDE) and Saft (SAFT) as EnerSys gains scale.

U.S. defense suppliers may see increased demand, while Ultralife's international operations could benefit from broader EnerSys distribution.

The deal highlights growing defense spending, potentially influencing broader industrial and aerospace sectors.

Counterpoint

If integration costs exceed expectations, EnerSys could face margin compression, making the deal less accretive.

Key entities

  • Shawn O’Connell

    President and CEO of EnerSys, announced the acquisition.

  • Michael Manna

    President and CEO of Ultralife, commented on the deal.

Related articles

$ULBIMed

Freedom: Ultralife upside after acquisition announcement is almost exhausted

Ultralife (ULBI) shares rose 145.4% to $15.61 after EnerSys (ENS) agreed to acquire it for $16 per share, a 166% premium. The deal, valued at $320M, is expected to close in Q1 2027. Analyst Vladimir Chernov sees limited upside for ULBI, with shares likely staying in the $15.5–16 range until the deal closes. ENS expects cost savings and EPS growth post-acquisition.

$ENSHighAI 9/10

EnerSys Pays 166% Premium for Ultralife to Expand Defense Batteries

EnerSys (ENS) will acquire Ultralife (ULBI) for $16.00 per share, a 166% premium, with a $320M enterprise value. The deal expands EnerSys' defense business, adding U.S. manufacturing for compliant batteries. EnerSys expects $15M-$20M in annual cost synergies and EPS growth within 18 months. Ultralife's 2025 revenue was $191M. The deal, funded by cash, requires majority shareholder approval and regulatory clearance, expected to close in Q1 2027.

$ULBIHigh

Ultralife to Be Acquired by EnerSys for $16 Per Share in Cash

Ultralife (ULBI) agreed to be acquired by EnerSys for $16 per share in cash. The deal requires a tender offer and merger, with no financing condition. Stockholders owning 40.3% of shares support the deal but do not meet the minimum tender condition alone. The merger agreement includes repayment of Ultralife's outstanding credit agreement at closing.